抗中性粒细胞胞质抗体相关性血管炎中的肺泡出血:国际随机对照试验(PEXIVAS)结果
PEXIVAS试验纳入704例AAV患者,随机接受血浆置换(PLEX)或无PLEX、减量或标准剂量糖皮质激素(GC)。入组时191例(27.1%)有弥漫性肺泡出血(DAH),其中61例为重度,包括29例机械通气。DAH患者1年死亡23/191(12.0%),无DAH患者死亡34/513(6.6%)。DAH亚组中,PLEX组1年死亡8/95(8.4%)vs 无PLEX组15/96(15.6%)(HR 0.52,95%CI 0.21-1.24);减量GC组死亡13/96(13.5%)vs 标准GC组10/95(10.5%)(HR 1.33,95%CI 0.57-3.13)。治疗对死亡率的影响不因DAH存在或严重程度而异。终末期肾病和严重感染在DAH状态或治疗间无差异。
要点
- DAH患者1年死亡23/191(12.0%)vs 无DAH患者34/513(6.6%),DAH为高危表现。
- DAH亚组中PLEX组1年死亡8/95(8.4%)vs 无PLEX组15/96(15.6%),HR 0.52(95%CI 0.21-1.24),未达统计学显著。
- DAH亚组中减量GC组1年死亡13/96(13.5%)vs 标准GC组10/95(10.5%),HR 1.33(95%CI 0.57-3.13),未达统计学显著。
- 机械通气患者中,PLEX vs 无PLEX无呼吸机天数中位数25(IQR 22-26)vs 22(IQR 22-27);减量GC vs 标准GC为23(IQR 20-25)vs 26(IQR 25-28)。
- 治疗对死亡率的影响不因DAH存在或严重程度而异;终末期肾病和严重感染无差异。
适用人群与场景
- PEXIVAS随机纳入704例AAV患者,入组时按DAH状态分为无DAH(n=513,72.9%)、非重度DAH、重度DAH(n=61,包括29例机械通气)。
- DAH患者较无DAH患者更年轻、更常复发、PR3-ANCA阳性、血清肌酐更低但更常接受透析。
诊断标准与关键阈值
- DAH状态在入组时定义:无DAH、非重度、重度(脉搏血氧饱和度在室内空气中⩽85%,或使用机械通气)。
研究设计与关键结果
- PEXIVAS为国际随机对照试验,纳入704例AAV患者,随机接受血浆置换(PLEX)或无PLEX、减量或标准剂量糖皮质激素(GC)。
- 入组时191例(27.1%)有DAH(61例重度,包括29例通气),无DAH 513例(72.9%)。
- DAH亚组中,PLEX组1年死亡8/95(8.4%)vs 无PLEX组15/96(15.6%),HR 0.52(95%CI 0.21-1.24)。
- DAH亚组中,减量GC组1年死亡13/96(13.5%)vs 标准GC组10/95(10.5%),HR 1.33(95%CI 0.57-3.13)。
- 机械通气患者中,PLEX vs 无PLEX无呼吸机天数中位数25(IQR 22-26)vs 22(IQR 22-27);减量GC vs 标准GC为23(IQR 20-25)vs 26(IQR 25-28)。
- 治疗对死亡率的影响不因DAH存在或严重程度而异。
- DAH患者1年死亡23/191(12.0%)vs 无DAH患者34/513(6.6%)。
- 终末期肾病和严重感染在DAH状态或治疗间无差异。
证据类型、等级与局限
- 证据类型:国际随机对照试验(PEXIVAS,NCT00987389)。
- 局限:原文结论指出需进一步数据确认或反驳PLEX或GC剂量对死亡率的获益。
对床旁实践的改变
- 作者认为,需进一步数据确认或反驳PLEX或GC剂量对DAH患者死亡率的获益;治疗对死亡率的影响不因DAH存在或严重程度而异。
指南或共识出处
- PEXIVAS试验(NCT00987389),发表于Am J Respir Crit Care Med。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Rationale: Diffuse alveolar hemorrhage (DAH) is a life-threatening manifestation of antineutrophil cytoplasmic antibody-associated vasculitis (AAV). The PEXIVAS (Plasma Exchange and Glucocorticoids in Severe Antineutrophil Cytoplasmic Antibody-Associated Vasculitis) (NCT00987389) trial was the largest in AAV and the first to enroll participants with DAH requiring mechanical ventilation. Objectives: Evaluate characteristics, treatment effects, and outcomes for patients with AAV with and without DAH. Methods: PEXIVAS randomized 704 participants to plasma exchange (PLEX) or no-PLEX and reduced or standard-dose glucocorticoids (GC). DAH status was defined at enrollment as no-DAH, nonsevere, or severe (room air oxygen saturation of ⩽ 85% as measured by pulse oximetry, or use of mechanical ventilation). Measurements and Main Results: At enrollment, 191 (27.1%) participants had DAH (61 severe, including 29 ventilated) and were younger, more frequently relapsing, PR3 (proteinase 3)-ANCA positive, and had lower serum creatinine but were more frequently dialyzed than participants without DAH (n = 513; 72.9%). Among those with DAH, 8/95 (8.4%) receiving PLEX died within 1 year versus 15/96 (15.6%) with no-PLEX (hazard ratio, 0.52; confidence interval [CI], 0.21-1.24), whereas 13/96 (13.5%) receiving reduced GC died versus 10/95 (10.5%) with standard GC (hazard ratio, 1.33; CI, 0.57-3.13). When ventilated, ventilator-free days were similar with PLEX versus no-PLEX (medians, 25; interquartile range [IQR], 22-26 vs. 22-27) and fewer with reduced GC (median, 23; IQR, 20-25) versus standard GC (median, 26; IQR, 25-28). Treatment effects on mortality did not vary by presence or severity of DAH. Overall, 23/191 (12.0%) with DAH died within 1 year versus 34/513 (6.6%) without DAH. End-stage kidney disease and serious infections did not differ by DAH status or treatments. Conclusions: Patients with AAV and DAH differ from those without DAH in multiple ways. Further data are required to confirm or refute a benefit of PLEX or GC dosing on mortality. Original clinical trial registered with www.clinicaltrials.gov (NCT00987389).
参考来源
- Fussner LA, Flores-Suárez LF, Cartin-Ceba R, et al. Alveolar Hemorrhage in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Results of an International Randomized Controlled Trial (PEXIVAS). Am J Respir Crit Care Med. 2024. PMID: 38346237. doi:10.1164/rccm.202308-1426OC
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。